HK Stock Market Move | DINGDANG HEALTH (09886) rose more than 5%, the company increased its investment in the weight loss market layout and advanced cooperation with original research pharmaceutical companies.

DINGDANG HEALTH (09886) rose by more than 5%, reaching 6.82% at the time of publication, at a price of 0.94 Hong Kong dollars, with a turnover of 5.24 million Hong Kong dollars. On the news front, recently, DINGDANG HEALTH announced a cooperation with Lilly Group. Following the Beijing region, DINGDANG HEALTH has officially launched the Therapeutic Peptide Injection (Mufengda) in pharmacies in Guangzhou and Shenzhen. Tianfeng research report states that in 2020, over 2.6 billion people globally have been affected by overweight/obesity, and the weight loss market continues to expand, with Lilly being one of the leading companies in the weight loss sector. DINGDANG HEALTH stated that, relying on Lilly's excellent innovative drug products, professional health education capabilities, DINGDANG HEALTH's extensive multifunctional smart pharmacy network, end-to-end intelligent warehouse distribution system, professional doctor-pharmacist service team, and a comprehensive health management system throughout the lifecycle, both parties will jointly provide a one-stop health solution for overweight/obese, diabetic, and other groups, enhancing the accessibility of medication and the level of health management.